Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dynamic Whole-Body PET-CT to Assess Glucose Uptake and Perfusion During GIP and GLP-1 Infusion
NCT07398300Recruiting
- Sponsor
- Rigshospitalet
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of glucose-dependent insulinotropic polypeptide[1-42] and Glucagon-like peptide 1 in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Rigshospitalet. Primary endpoint: Metabolic Rate of FDG at 75 minutes. Started Mar 2026; status: recruiting.
02
Drugs
glucose-dependent insulinotropic polypeptide[1-42]Glucagon-like peptide 1
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07398300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07398300.